Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report
about
The Place of FDG PET/CT in Renal Cell Carcinoma: Value and LimitationsUpdate on advances in molecular PET in urological oncologyCan Initial (18)F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP studyThe early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease courseThe maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancerManagement of urological malignancies: Has positron emission tomography/computed tomography made a difference?Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancerMetabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical ImplicationsFDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.FDG PET or PET/CT in evaluation of renal angiomyolipomaAlternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.Molecular imaging of urogenital diseases.The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.Positron emission tomography/computed tomography imaging features of renal cell carcinoma and pulmonary metastases in a dog.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies.Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.Assessment of cell proliferation in renal cell carcinoma using dual-phase (18)F-fluorodeoxyglucose PET/CTPrognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy.Oncocytoma: A Differential Consideration for an Incidentally Detected FDG-Avid Renal Mass on PET/CT.PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
P2860
Q28070239-3B2E2900-A172-4C62-840D-254159EC5C2AQ33625389-9A11A059-9F28-4B6B-A7E3-585868952626Q33639383-68568A02-C6A4-49A6-BFD6-36318E917CD1Q33755947-FBD5B05A-9F14-45D5-B511-4F48A0F7D38FQ33792683-FDAE5285-33C5-4273-AFC0-BB99AD72E17AQ34253776-52573A63-4EDA-4E45-8CC9-01DD2E14146BQ34569318-96142E6C-14D0-4FEF-9C96-8BA2014DA4C1Q34990800-CEDDE2B6-3F45-4977-B5DF-30953EC208BDQ35169825-E5FFD772-2F0B-4F72-B771-BC18F057E18AQ35915703-DBF675AB-2F85-4492-9645-F96C11BB4402Q35917780-768C5C16-FD04-47C6-9E38-9F67FA4211D1Q36001780-9421FC7F-63A0-446B-99F0-F4A94F1C4D25Q36567385-DE03C0B8-D98C-4B38-8332-8AE5D2968A90Q36662636-5BF43BFA-0339-48C6-9E52-E4401C215E45Q37014111-17C691D0-9308-4F7D-BD74-65AA63FBA1C1Q37550399-20C2D865-CA97-4946-B2E1-AFE71B0782A5Q37576212-D69F54CA-2CE0-4F02-AF81-A776F3B3964EQ37711287-69341C09-1F1E-4AD1-BD4E-7FA61353CC37Q38196855-130AF44F-AD4A-4460-B03E-CE404C722647Q38837758-0C5BE090-356A-490B-8210-05CC859D535BQ41660750-A4C150BF-7E5D-45E9-A73A-7487AB889A37Q42363905-931AB395-95E1-425B-ADB2-979ABADED6A3Q45823946-72DB2B4C-5EEE-446D-8FED-A1E0ACA316F3Q47094599-CA1B9FB4-5ACE-4374-A7D9-466232349395Q49165684-1B8DE2F2-4C7E-4A36-A762-5971468B3B26Q52780316-D3002B90-E9F7-4082-91BD-8B660BF66AAFQ52877176-D49A325E-D235-4F74-B508-87F0E24B2589
P2860
Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of maximum standardized ...... arcinoma: a preliminary report
@ast
Impact of maximum standardized ...... arcinoma: a preliminary report
@en
type
label
Impact of maximum standardized ...... arcinoma: a preliminary report
@ast
Impact of maximum standardized ...... arcinoma: a preliminary report
@en
prefLabel
Impact of maximum standardized ...... arcinoma: a preliminary report
@ast
Impact of maximum standardized ...... arcinoma: a preliminary report
@en
P2093
P2860
P356
P1433
P1476
Impact of maximum standardized ...... arcinoma: a preliminary report
@en
P2093
Futoshi Sano
Hanako Ishigaki
Kazuhide Makiyama
Kazuhiro Namura
Kazuki Kobayashi
Masahiro Yao
Narihiko Hayashi
Noboru Nakaigawa
Ryogo Minamimoto
Sumio Noguchi
P2860
P2888
P356
10.1186/1471-2407-10-667
P407
P577
2010-12-03T00:00:00Z
P5875
P6179
1031120077